Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ADDITIONAL USE OF TRIMETAZIDINE IN PATIENTS WITH CHRONIC HEART FAILURE. A META-ANALYSIS

https://doi.org/10.20996/1819-6446-2012-8-2-242-250

Full Text:

About the Authors

Lei Zhang

Russian Federation


Yizhou Lu

Russian Federation


Hong Jiang

Russian Federation


Liming Zhang

Russian Federation


Aijun Sun

Russian Federation


Yunzeng Zou

Russian Federation


Junbo Ge

Russian Federation


References

1. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009;81:412–9. 2. Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 1996;28:341–50.

2. Kantor PF , Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580–8.

3. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coronary Artery Dis 2003;14:171–9.

4. Ruixing Y , Wenwu L, Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Transl Res 2007;149:152–60.

5. Williams FM, T anda K, Kus M, Williams TJ. T rimetazidine inhibits neutrophil accumulation after myocardial-ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993;22:828–33.

6. Di Napoli P , Chierchia S, Taccardi AA, et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide-Biol Ch 2007;16:228–36.

7. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001;22:2164–70.

8. Belardinelli R, Solenghi M, Volpe L, Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J 2007;28:1102–8.

9. Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F . Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol 2008;51:611–5.

10. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990;11:207–12.

11. Cera M, Salerno A, Fragasso G, et al. Beneficial electrophysiological effects of trimetazidine in patients with postischemic chronic heart failure. J Cardiovasc Pharmacol Ther 2010;15:24–30.

12. Di Napoli P , Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91:161–5.

13. Di Napoli P , Di Giovanni P , Gaeta MA, D’Apolito G, Barsotti A. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy. Am Heart J 2007;154:602.e1–5.

14. El-Kady T , El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005;5:271–8.

15. Fragasso G, Palloshi A, Puccetti P , et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor , in patients with heart failure. J Am Coll Cardiol 2006;48:992–8.

16. Gunes Y , Guntekin U, Tuncer M, Sahin M. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 2009;24:277–82.

17. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003;2:16.

18. Sisakian H, Torgomyan A, Barkhudaryan A, Sisakian H, Torgomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic car- diomyopathy. Acta Cardiol 2007;62:493–9.

19. Thrainsdottir IS, von Bibra H, Malmberg K, Ryden L. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 2004;44:101–8. 21. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator , has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008;118:1250–8.

20. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814–21.

21. Zemljic G, Bunc M, Vrtovec B. Trimetazidine shortens QTc interval in patients with ischemic heart failure. J Cardiovasc Pharmacol Ther 2010;15:31–6.

22. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions — Potential for pharmacological interventions. Cardiovasc Res 1997;33:243–57.

23. Katz AM. Is the failing heart energy depleted? Cardiol Clin 1998;16:633–44.

24. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004;25:634–41.

25. Deleiris J, Boucher F . Rationale for trimetazidine administration in myocardial-ischemia reperfusion syndrome. Eur Heart J 1993;14:34–40.

26. Levin ER, Gardner DG, Samson WK. Mechanisms of disease - Natriuretic peptides. New Engl J Med 1998;339:321–8.

27. Kiyosue T , Nakamura S, Arita M. Effects of trimetazidine on action potentials and membrane currents of guinea-pig ventricular myocytes. J Mol Cell Cardiol 1986;18:1301–11.

28. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;91:988–98.

29. Genissel P , Chodjania Y , Demolis JL, Ragueneau I, Jaillon P . Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. Eur J Drug Metab Pharmacokinet 2004;29:61–8.


For citation:


Zhang L., Lu Y., Jiang H., Zhang L., Sun A., Zou Yu., Ge J. ADDITIONAL USE OF TRIMETAZIDINE IN PATIENTS WITH CHRONIC HEART FAILURE. A META-ANALYSIS. Rational Pharmacotherapy in Cardiology. 2012;8(2):242-250. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-2-242-250

Views: 1119


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)